nodes	percent_of_prediction	percent_of_DWPC	metapath
Sibutramine—CYP3A4—Cytarabine—lymphatic system cancer	0.0472	0.318	CbGbCtD
Sibutramine—CYP3A4—Teniposide—lymphatic system cancer	0.0465	0.313	CbGbCtD
Sibutramine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0325	0.219	CbGbCtD
Sibutramine—CYP3A4—Vincristine—lymphatic system cancer	0.0224	0.151	CbGbCtD
Sibutramine—Angiopathy—Vincristine—lymphatic system cancer	0.00107	0.00126	CcSEcCtD
Sibutramine—Diarrhoea—Teniposide—lymphatic system cancer	0.00107	0.00125	CcSEcCtD
Sibutramine—Myalgia—Bleomycin—lymphatic system cancer	0.00105	0.00123	CcSEcCtD
Sibutramine—Chest pain—Bleomycin—lymphatic system cancer	0.00105	0.00123	CcSEcCtD
Sibutramine—Alopecia—Vincristine—lymphatic system cancer	0.00104	0.00122	CcSEcCtD
Sibutramine—Back pain—Carmustine—lymphatic system cancer	0.00104	0.00122	CcSEcCtD
Sibutramine—Discomfort—Bleomycin—lymphatic system cancer	0.00104	0.00122	CcSEcCtD
Sibutramine—Chills—Mitoxantrone—lymphatic system cancer	0.00103	0.00121	CcSEcCtD
Sibutramine—Bladder pain—Methotrexate—lymphatic system cancer	0.00103	0.00121	CcSEcCtD
Sibutramine—Mouth ulceration—Methotrexate—lymphatic system cancer	0.00103	0.00121	CcSEcCtD
Sibutramine—Neoplasm—Methotrexate—lymphatic system cancer	0.00103	0.00121	CcSEcCtD
Sibutramine—Ecchymosis—Methotrexate—lymphatic system cancer	0.00103	0.00121	CcSEcCtD
Sibutramine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00103	0.00121	CcSEcCtD
Sibutramine—Alopecia—Mitoxantrone—lymphatic system cancer	0.00102	0.00119	CcSEcCtD
Sibutramine—Confusional state—Bleomycin—lymphatic system cancer	0.00101	0.00119	CcSEcCtD
Sibutramine—Vision blurred—Carmustine—lymphatic system cancer	0.00101	0.00119	CcSEcCtD
Sibutramine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00101	0.00119	CcSEcCtD
Sibutramine—Tremor—Carmustine—lymphatic system cancer	0.00101	0.00118	CcSEcCtD
Sibutramine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00101	0.00118	CcSEcCtD
Sibutramine—Oedema—Bleomycin—lymphatic system cancer	0.00101	0.00118	CcSEcCtD
Sibutramine—Infection—Bleomycin—lymphatic system cancer	0.001	0.00117	CcSEcCtD
Sibutramine—Anaemia—Carmustine—lymphatic system cancer	0.000995	0.00117	CcSEcCtD
Sibutramine—Back pain—Vincristine—lymphatic system cancer	0.000994	0.00117	CcSEcCtD
Sibutramine—Vomiting—Teniposide—lymphatic system cancer	0.000993	0.00117	CcSEcCtD
Sibutramine—Sepsis—Methotrexate—lymphatic system cancer	0.000989	0.00116	CcSEcCtD
Sibutramine—Agitation—Carmustine—lymphatic system cancer	0.000989	0.00116	CcSEcCtD
Sibutramine—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000985	0.00116	CcSEcCtD
Sibutramine—Asthenia—Fludarabine—lymphatic system cancer	0.000985	0.00116	CcSEcCtD
Sibutramine—Rash—Teniposide—lymphatic system cancer	0.000985	0.00116	CcSEcCtD
Sibutramine—Dermatitis—Teniposide—lymphatic system cancer	0.000984	0.00116	CcSEcCtD
Sibutramine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00098	0.00115	CcSEcCtD
Sibutramine—Headache—Teniposide—lymphatic system cancer	0.000978	0.00115	CcSEcCtD
Sibutramine—Pruritus—Fludarabine—lymphatic system cancer	0.000971	0.00114	CcSEcCtD
Sibutramine—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00097	0.00114	CcSEcCtD
Sibutramine—Back pain—Mitoxantrone—lymphatic system cancer	0.000968	0.00114	CcSEcCtD
Sibutramine—Leukopenia—Carmustine—lymphatic system cancer	0.000963	0.00113	CcSEcCtD
Sibutramine—Anorexia—Bleomycin—lymphatic system cancer	0.000959	0.00113	CcSEcCtD
Sibutramine—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000952	0.00112	CcSEcCtD
Sibutramine—Anaemia—Vincristine—lymphatic system cancer	0.000949	0.00112	CcSEcCtD
Sibutramine—Agitation—Vincristine—lymphatic system cancer	0.000944	0.00111	CcSEcCtD
Sibutramine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000943	0.00111	CcSEcCtD
Sibutramine—Photosensitivity—Methotrexate—lymphatic system cancer	0.000943	0.00111	CcSEcCtD
Sibutramine—Hypotension—Bleomycin—lymphatic system cancer	0.00094	0.0011	CcSEcCtD
Sibutramine—Diarrhoea—Fludarabine—lymphatic system cancer	0.000939	0.0011	CcSEcCtD
Sibutramine—Convulsion—Carmustine—lymphatic system cancer	0.000932	0.0011	CcSEcCtD
Sibutramine—Hypertension—Carmustine—lymphatic system cancer	0.000929	0.00109	CcSEcCtD
Sibutramine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000928	0.00109	CcSEcCtD
Sibutramine—Nausea—Teniposide—lymphatic system cancer	0.000927	0.00109	CcSEcCtD
Sibutramine—Anaemia—Mitoxantrone—lymphatic system cancer	0.000925	0.00109	CcSEcCtD
Sibutramine—Vertigo—Vincristine—lymphatic system cancer	0.000923	0.00108	CcSEcCtD
Sibutramine—Leukopenia—Vincristine—lymphatic system cancer	0.00092	0.00108	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000917	0.00108	CcSEcCtD
Sibutramine—Chest pain—Carmustine—lymphatic system cancer	0.000916	0.00108	CcSEcCtD
Sibutramine—Myalgia—Carmustine—lymphatic system cancer	0.000916	0.00108	CcSEcCtD
Sibutramine—Anxiety—Carmustine—lymphatic system cancer	0.000913	0.00107	CcSEcCtD
Sibutramine—Paraesthesia—Bleomycin—lymphatic system cancer	0.000903	0.00106	CcSEcCtD
Sibutramine—Malaise—Mitoxantrone—lymphatic system cancer	0.000902	0.00106	CcSEcCtD
Sibutramine—Dyspnoea—Bleomycin—lymphatic system cancer	0.000897	0.00105	CcSEcCtD
Sibutramine—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000896	0.00105	CcSEcCtD
Sibutramine—Convulsion—Vincristine—lymphatic system cancer	0.00089	0.00105	CcSEcCtD
Sibutramine—Hypertension—Vincristine—lymphatic system cancer	0.000887	0.00104	CcSEcCtD
Sibutramine—Confusional state—Carmustine—lymphatic system cancer	0.000886	0.00104	CcSEcCtD
Sibutramine—Oedema—Carmustine—lymphatic system cancer	0.000878	0.00103	CcSEcCtD
Sibutramine—Decreased appetite—Bleomycin—lymphatic system cancer	0.000875	0.00103	CcSEcCtD
Sibutramine—Myalgia—Vincristine—lymphatic system cancer	0.000875	0.00103	CcSEcCtD
Sibutramine—Cough—Mitoxantrone—lymphatic system cancer	0.000873	0.00103	CcSEcCtD
Sibutramine—Infection—Carmustine—lymphatic system cancer	0.000873	0.00102	CcSEcCtD
Sibutramine—Vomiting—Fludarabine—lymphatic system cancer	0.000873	0.00102	CcSEcCtD
Sibutramine—Convulsion—Mitoxantrone—lymphatic system cancer	0.000867	0.00102	CcSEcCtD
Sibutramine—Rash—Fludarabine—lymphatic system cancer	0.000865	0.00102	CcSEcCtD
Sibutramine—Dermatitis—Fludarabine—lymphatic system cancer	0.000864	0.00102	CcSEcCtD
Sibutramine—Hypertension—Mitoxantrone—lymphatic system cancer	0.000864	0.00101	CcSEcCtD
Sibutramine—Pain—Bleomycin—lymphatic system cancer	0.00086	0.00101	CcSEcCtD
Sibutramine—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00086	0.00101	CcSEcCtD
Sibutramine—Headache—Fludarabine—lymphatic system cancer	0.00086	0.00101	CcSEcCtD
Sibutramine—Tachycardia—Carmustine—lymphatic system cancer	0.000857	0.00101	CcSEcCtD
Sibutramine—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000855	0.001	CcSEcCtD
Sibutramine—Chest pain—Mitoxantrone—lymphatic system cancer	0.000852	0.001	CcSEcCtD
Sibutramine—Myalgia—Mitoxantrone—lymphatic system cancer	0.000852	0.001	CcSEcCtD
Sibutramine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000852	0.001	CcSEcCtD
Sibutramine—Anxiety—Mitoxantrone—lymphatic system cancer	0.000849	0.000997	CcSEcCtD
Sibutramine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000845	0.000992	CcSEcCtD
Sibutramine—Discomfort—Mitoxantrone—lymphatic system cancer	0.000842	0.000988	CcSEcCtD
Sibutramine—Oedema—Vincristine—lymphatic system cancer	0.000838	0.000985	CcSEcCtD
Sibutramine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000838	0.000985	CcSEcCtD
Sibutramine—Anorexia—Carmustine—lymphatic system cancer	0.000837	0.000983	CcSEcCtD
Sibutramine—Infection—Vincristine—lymphatic system cancer	0.000833	0.000978	CcSEcCtD
Sibutramine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000829	0.000974	CcSEcCtD
Sibutramine—Osteoarthritis—Methotrexate—lymphatic system cancer	0.000828	0.000972	CcSEcCtD
Sibutramine—Confusional state—Mitoxantrone—lymphatic system cancer	0.000823	0.000967	CcSEcCtD
Sibutramine—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000821	0.000964	CcSEcCtD
Sibutramine—Hypotension—Carmustine—lymphatic system cancer	0.000821	0.000964	CcSEcCtD
Sibutramine—Oedema—Mitoxantrone—lymphatic system cancer	0.000817	0.000959	CcSEcCtD
Sibutramine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000817	0.000959	CcSEcCtD
Sibutramine—Nausea—Fludarabine—lymphatic system cancer	0.000815	0.000957	CcSEcCtD
Sibutramine—Infection—Mitoxantrone—lymphatic system cancer	0.000811	0.000953	CcSEcCtD
Sibutramine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000811	0.000952	CcSEcCtD
Sibutramine—Shock—Mitoxantrone—lymphatic system cancer	0.000803	0.000943	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.0008	0.00094	CcSEcCtD
Sibutramine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000799	0.000939	CcSEcCtD
Sibutramine—Urticaria—Bleomycin—lymphatic system cancer	0.000799	0.000939	CcSEcCtD
Sibutramine—Anorexia—Vincristine—lymphatic system cancer	0.000799	0.000939	CcSEcCtD
Sibutramine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000797	0.000936	CcSEcCtD
Sibutramine—Body temperature increased—Bleomycin—lymphatic system cancer	0.000795	0.000934	CcSEcCtD
Sibutramine—Insomnia—Carmustine—lymphatic system cancer	0.000794	0.000933	CcSEcCtD
Sibutramine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000793	0.000931	CcSEcCtD
Sibutramine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000789	0.000927	CcSEcCtD
Sibutramine—Paraesthesia—Carmustine—lymphatic system cancer	0.000789	0.000926	CcSEcCtD
Sibutramine—Mood swings—Methotrexate—lymphatic system cancer	0.000784	0.000921	CcSEcCtD
Sibutramine—Hypotension—Vincristine—lymphatic system cancer	0.000783	0.00092	CcSEcCtD
Sibutramine—Dyspnoea—Carmustine—lymphatic system cancer	0.000783	0.00092	CcSEcCtD
Sibutramine—Somnolence—Carmustine—lymphatic system cancer	0.000781	0.000917	CcSEcCtD
Sibutramine—Anorexia—Mitoxantrone—lymphatic system cancer	0.000778	0.000914	CcSEcCtD
Sibutramine—Ataxia—Methotrexate—lymphatic system cancer	0.000778	0.000914	CcSEcCtD
Sibutramine—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000764	0.000897	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000764	0.000897	CcSEcCtD
Sibutramine—Decreased appetite—Carmustine—lymphatic system cancer	0.000763	0.000897	CcSEcCtD
Sibutramine—Hypotension—Mitoxantrone—lymphatic system cancer	0.000763	0.000896	CcSEcCtD
Sibutramine—Insomnia—Vincristine—lymphatic system cancer	0.000758	0.000891	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000758	0.000891	CcSEcCtD
Sibutramine—Paraesthesia—Vincristine—lymphatic system cancer	0.000753	0.000884	CcSEcCtD
Sibutramine—Pain—Carmustine—lymphatic system cancer	0.000751	0.000882	CcSEcCtD
Sibutramine—Constipation—Carmustine—lymphatic system cancer	0.000751	0.000882	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000744	0.000874	CcSEcCtD
Sibutramine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000741	0.000871	CcSEcCtD
Sibutramine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000733	0.000861	CcSEcCtD
Sibutramine—Decreased appetite—Vincristine—lymphatic system cancer	0.000729	0.000856	CcSEcCtD
Sibutramine—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000728	0.000855	CcSEcCtD
Sibutramine—Somnolence—Mitoxantrone—lymphatic system cancer	0.000726	0.000853	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000724	0.00085	CcSEcCtD
Sibutramine—Feeling abnormal—Carmustine—lymphatic system cancer	0.000724	0.00085	CcSEcCtD
Sibutramine—Asthenia—Bleomycin—lymphatic system cancer	0.000722	0.000848	CcSEcCtD
Sibutramine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000719	0.000844	CcSEcCtD
Sibutramine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000718	0.000843	CcSEcCtD
Sibutramine—Constipation—Vincristine—lymphatic system cancer	0.000717	0.000842	CcSEcCtD
Sibutramine—Pain—Vincristine—lymphatic system cancer	0.000717	0.000842	CcSEcCtD
Sibutramine—Asthma—Methotrexate—lymphatic system cancer	0.000715	0.00084	CcSEcCtD
Sibutramine—Pruritus—Bleomycin—lymphatic system cancer	0.000712	0.000836	CcSEcCtD
Sibutramine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00071	0.000834	CcSEcCtD
Sibutramine—Eosinophilia—Methotrexate—lymphatic system cancer	0.000708	0.000832	CcSEcCtD
Sibutramine—Constipation—Mitoxantrone—lymphatic system cancer	0.000698	0.00082	CcSEcCtD
Sibutramine—Pain—Mitoxantrone—lymphatic system cancer	0.000698	0.00082	CcSEcCtD
Sibutramine—Abdominal pain—Carmustine—lymphatic system cancer	0.000694	0.000815	CcSEcCtD
Sibutramine—Body temperature increased—Carmustine—lymphatic system cancer	0.000694	0.000815	CcSEcCtD
Sibutramine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000686	0.000805	CcSEcCtD
Sibutramine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000673	0.00079	CcSEcCtD
Sibutramine—Dysuria—Methotrexate—lymphatic system cancer	0.000669	0.000786	CcSEcCtD
Sibutramine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000668	0.000784	CcSEcCtD
Sibutramine—Abdominal pain—Vincristine—lymphatic system cancer	0.000663	0.000778	CcSEcCtD
Sibutramine—Body temperature increased—Vincristine—lymphatic system cancer	0.000663	0.000778	CcSEcCtD
Sibutramine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000659	0.000774	CcSEcCtD
Sibutramine—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.000653	0.000767	CcSEcCtD
Sibutramine—Urticaria—Mitoxantrone—lymphatic system cancer	0.000649	0.000762	CcSEcCtD
Sibutramine—Hypersensitivity—Carmustine—lymphatic system cancer	0.000647	0.00076	CcSEcCtD
Sibutramine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000645	0.000758	CcSEcCtD
Sibutramine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000645	0.000758	CcSEcCtD
Sibutramine—Pneumonia—Methotrexate—lymphatic system cancer	0.000642	0.000753	CcSEcCtD
Sibutramine—Vomiting—Bleomycin—lymphatic system cancer	0.00064	0.000751	CcSEcCtD
Sibutramine—Depression—Methotrexate—lymphatic system cancer	0.000636	0.000747	CcSEcCtD
Sibutramine—Rash—Bleomycin—lymphatic system cancer	0.000634	0.000745	CcSEcCtD
Sibutramine—Dermatitis—Bleomycin—lymphatic system cancer	0.000634	0.000744	CcSEcCtD
Sibutramine—Asthenia—Carmustine—lymphatic system cancer	0.00063	0.00074	CcSEcCtD
Sibutramine—Renal failure—Methotrexate—lymphatic system cancer	0.000627	0.000736	CcSEcCtD
Sibutramine—Stomatitis—Methotrexate—lymphatic system cancer	0.000622	0.00073	CcSEcCtD
Sibutramine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00062	0.000728	CcSEcCtD
Sibutramine—Hypersensitivity—Vincristine—lymphatic system cancer	0.000618	0.000725	CcSEcCtD
Sibutramine—Sweating—Methotrexate—lymphatic system cancer	0.000612	0.000718	CcSEcCtD
Sibutramine—Haematuria—Methotrexate—lymphatic system cancer	0.000608	0.000714	CcSEcCtD
Sibutramine—Epistaxis—Methotrexate—lymphatic system cancer	0.000602	0.000707	CcSEcCtD
Sibutramine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000602	0.000707	CcSEcCtD
Sibutramine—Asthenia—Vincristine—lymphatic system cancer	0.000602	0.000706	CcSEcCtD
Sibutramine—Diarrhoea—Carmustine—lymphatic system cancer	0.000601	0.000706	CcSEcCtD
Sibutramine—Nausea—Bleomycin—lymphatic system cancer	0.000598	0.000702	CcSEcCtD
Sibutramine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000586	0.000688	CcSEcCtD
Sibutramine—Dizziness—Carmustine—lymphatic system cancer	0.000581	0.000682	CcSEcCtD
Sibutramine—Haemoglobin—Methotrexate—lymphatic system cancer	0.000576	0.000676	CcSEcCtD
Sibutramine—Diarrhoea—Vincristine—lymphatic system cancer	0.000574	0.000674	CcSEcCtD
Sibutramine—Haemorrhage—Methotrexate—lymphatic system cancer	0.000573	0.000673	CcSEcCtD
Sibutramine—Pharyngitis—Methotrexate—lymphatic system cancer	0.000568	0.000667	CcSEcCtD
Sibutramine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000559	0.000656	CcSEcCtD
Sibutramine—Vomiting—Carmustine—lymphatic system cancer	0.000558	0.000656	CcSEcCtD
Sibutramine—Dizziness—Vincristine—lymphatic system cancer	0.000554	0.000651	CcSEcCtD
Sibutramine—Rash—Carmustine—lymphatic system cancer	0.000554	0.00065	CcSEcCtD
Sibutramine—Dermatitis—Carmustine—lymphatic system cancer	0.000553	0.00065	CcSEcCtD
Sibutramine—Visual impairment—Methotrexate—lymphatic system cancer	0.000552	0.000648	CcSEcCtD
Sibutramine—Headache—Carmustine—lymphatic system cancer	0.00055	0.000646	CcSEcCtD
Sibutramine—Eye disorder—Methotrexate—lymphatic system cancer	0.000535	0.000628	CcSEcCtD
Sibutramine—Tinnitus—Methotrexate—lymphatic system cancer	0.000534	0.000627	CcSEcCtD
Sibutramine—Vomiting—Vincristine—lymphatic system cancer	0.000533	0.000626	CcSEcCtD
Sibutramine—Rash—Vincristine—lymphatic system cancer	0.000529	0.000621	CcSEcCtD
Sibutramine—Dermatitis—Vincristine—lymphatic system cancer	0.000528	0.00062	CcSEcCtD
Sibutramine—Headache—Vincristine—lymphatic system cancer	0.000525	0.000617	CcSEcCtD
Sibutramine—Nausea—Carmustine—lymphatic system cancer	0.000522	0.000613	CcSEcCtD
Sibutramine—Angiopathy—Methotrexate—lymphatic system cancer	0.00052	0.00061	CcSEcCtD
Sibutramine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000519	0.00061	CcSEcCtD
Sibutramine—Immune system disorder—Methotrexate—lymphatic system cancer	0.000517	0.000607	CcSEcCtD
Sibutramine—Rash—Mitoxantrone—lymphatic system cancer	0.000515	0.000605	CcSEcCtD
Sibutramine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000514	0.000604	CcSEcCtD
Sibutramine—Chills—Methotrexate—lymphatic system cancer	0.000514	0.000603	CcSEcCtD
Sibutramine—Headache—Mitoxantrone—lymphatic system cancer	0.000512	0.000601	CcSEcCtD
Sibutramine—Alopecia—Methotrexate—lymphatic system cancer	0.000506	0.000594	CcSEcCtD
Sibutramine—Malnutrition—Methotrexate—lymphatic system cancer	0.000498	0.000585	CcSEcCtD
Sibutramine—Nausea—Vincristine—lymphatic system cancer	0.000498	0.000585	CcSEcCtD
Sibutramine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000488	0.000573	CcSEcCtD
Sibutramine—Nausea—Mitoxantrone—lymphatic system cancer	0.000485	0.00057	CcSEcCtD
Sibutramine—Back pain—Methotrexate—lymphatic system cancer	0.000482	0.000566	CcSEcCtD
Sibutramine—Vision blurred—Methotrexate—lymphatic system cancer	0.00047	0.000552	CcSEcCtD
Sibutramine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000462	0.000543	CcSEcCtD
Sibutramine—Anaemia—Methotrexate—lymphatic system cancer	0.000461	0.000541	CcSEcCtD
Sibutramine—Malaise—Methotrexate—lymphatic system cancer	0.00045	0.000528	CcSEcCtD
Sibutramine—Vertigo—Methotrexate—lymphatic system cancer	0.000448	0.000526	CcSEcCtD
Sibutramine—Leukopenia—Methotrexate—lymphatic system cancer	0.000446	0.000524	CcSEcCtD
Sibutramine—Cough—Methotrexate—lymphatic system cancer	0.000435	0.000511	CcSEcCtD
Sibutramine—Convulsion—Methotrexate—lymphatic system cancer	0.000432	0.000507	CcSEcCtD
Sibutramine—Chest pain—Methotrexate—lymphatic system cancer	0.000424	0.000498	CcSEcCtD
Sibutramine—Myalgia—Methotrexate—lymphatic system cancer	0.000424	0.000498	CcSEcCtD
Sibutramine—Arthralgia—Methotrexate—lymphatic system cancer	0.000424	0.000498	CcSEcCtD
Sibutramine—Discomfort—Methotrexate—lymphatic system cancer	0.000419	0.000492	CcSEcCtD
Sibutramine—Confusional state—Methotrexate—lymphatic system cancer	0.00041	0.000482	CcSEcCtD
Sibutramine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000407	0.000478	CcSEcCtD
Sibutramine—Infection—Methotrexate—lymphatic system cancer	0.000404	0.000475	CcSEcCtD
Sibutramine—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000398	0.000468	CcSEcCtD
Sibutramine—Skin disorder—Methotrexate—lymphatic system cancer	0.000395	0.000464	CcSEcCtD
Sibutramine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000393	0.000462	CcSEcCtD
Sibutramine—Anorexia—Methotrexate—lymphatic system cancer	0.000388	0.000455	CcSEcCtD
Sibutramine—Hypotension—Methotrexate—lymphatic system cancer	0.00038	0.000446	CcSEcCtD
Sibutramine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000371	0.000435	CcSEcCtD
Sibutramine—Insomnia—Methotrexate—lymphatic system cancer	0.000368	0.000432	CcSEcCtD
Sibutramine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000365	0.000429	CcSEcCtD
Sibutramine—Dyspnoea—Methotrexate—lymphatic system cancer	0.000363	0.000426	CcSEcCtD
Sibutramine—Somnolence—Methotrexate—lymphatic system cancer	0.000362	0.000425	CcSEcCtD
Sibutramine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000358	0.000421	CcSEcCtD
Sibutramine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000354	0.000415	CcSEcCtD
Sibutramine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000351	0.000412	CcSEcCtD
Sibutramine—Pain—Methotrexate—lymphatic system cancer	0.000348	0.000409	CcSEcCtD
Sibutramine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000335	0.000394	CcSEcCtD
Sibutramine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000333	0.000391	CcSEcCtD
Sibutramine—Urticaria—Methotrexate—lymphatic system cancer	0.000323	0.00038	CcSEcCtD
Sibutramine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000322	0.000378	CcSEcCtD
Sibutramine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000322	0.000378	CcSEcCtD
Sibutramine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.0003	0.000352	CcSEcCtD
Sibutramine—Asthenia—Methotrexate—lymphatic system cancer	0.000292	0.000343	CcSEcCtD
Sibutramine—Pruritus—Methotrexate—lymphatic system cancer	0.000288	0.000338	CcSEcCtD
Sibutramine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000278	0.000327	CcSEcCtD
Sibutramine—Dizziness—Methotrexate—lymphatic system cancer	0.000269	0.000316	CcSEcCtD
Sibutramine—Vomiting—Methotrexate—lymphatic system cancer	0.000259	0.000304	CcSEcCtD
Sibutramine—Rash—Methotrexate—lymphatic system cancer	0.000257	0.000301	CcSEcCtD
Sibutramine—Dermatitis—Methotrexate—lymphatic system cancer	0.000256	0.000301	CcSEcCtD
Sibutramine—Headache—Methotrexate—lymphatic system cancer	0.000255	0.000299	CcSEcCtD
Sibutramine—Nausea—Methotrexate—lymphatic system cancer	0.000242	0.000284	CcSEcCtD
